Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Galvan

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Clinical Microbiology|January 5, 2000
Serodiagnosis of recently acquired Toxoplasma gondii infection with a recombinant antigenS Li, G Maine, Y Suzuki, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 14, 2004
Cholesteryl ester transfer protein TaqIB polymorphism and its relation to parameters of the insulin resistance syndrome in an Austrian cohortR Weitgasser, G Galvan, L Malaimare, et al.
Langenbecks Archiv Fur Chirurgie|January 1, 1990
[Partial lobe resection, or hemithyroidectomy in surgery of the isolated thyroid nodule?]O Boeckl, W Pimpl, G Galvan, et al.
The Prostate|August 1, 1997
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude miceA Jungwirth, G Galvan, J Pinski, et al.
Onkologie|July 7, 2001
Malignant glioma as a secondary malignant neoplasm after radiation therapy for craniopharyngioma: report of a case and review of reported casesM Kranzinger, N Jones, O Rittinger, et al.
European Journal of Nuclear Medicine|January 1, 1993
99mTc-DTPA aerosol for same-day post-perfusion ventilation imaging: results of a multicentre studyH Köhn, A Mostbeck, S Bachmayr, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-IIA Jungwirth, J Pinski, G Galvan, et al.
Acta Endocrinologica. Supplementum|January 1, 1987
Effects of high and low doses of methimazole in patients with Graves' thyrotoxicosisG Benker, D Reinwein, H Creutzig, et al.
Experimental and Clinical Endocrinology|May 1, 1991
Antithyroid drug treatment of von Basedow's disease: results from a multicenter studyG Benker, C Nolte, T Olbricht, et al.
Journal of Endocrinological Investigation|April 1, 1993
Clinical thyroidology 1992: "what do we really need'?G Riccabona, L J DeGroot, F Delange, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Clinical Microbiology|January 5, 2000
Serodiagnosis of recently acquired Toxoplasma gondii infection with a recombinant antigenS Li, G Maine, Y Suzuki, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 14, 2004
Cholesteryl ester transfer protein TaqIB polymorphism and its relation to parameters of the insulin resistance syndrome in an Austrian cohortR Weitgasser, G Galvan, L Malaimare, et al.
Langenbecks Archiv Fur Chirurgie|January 1, 1990
[Partial lobe resection, or hemithyroidectomy in surgery of the isolated thyroid nodule?]O Boeckl, W Pimpl, G Galvan, et al.
The Prostate|August 1, 1997
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude miceA Jungwirth, G Galvan, J Pinski, et al.
Onkologie|July 7, 2001
Malignant glioma as a secondary malignant neoplasm after radiation therapy for craniopharyngioma: report of a case and review of reported casesM Kranzinger, N Jones, O Rittinger, et al.
European Journal of Nuclear Medicine|January 1, 1993
99mTc-DTPA aerosol for same-day post-perfusion ventilation imaging: results of a multicentre studyH Köhn, A Mostbeck, S Bachmayr, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-IIA Jungwirth, J Pinski, G Galvan, et al.
Acta Endocrinologica. Supplementum|January 1, 1987
Effects of high and low doses of methimazole in patients with Graves' thyrotoxicosisG Benker, D Reinwein, H Creutzig, et al.
Experimental and Clinical Endocrinology|May 1, 1991
Antithyroid drug treatment of von Basedow's disease: results from a multicenter studyG Benker, C Nolte, T Olbricht, et al.
Journal of Endocrinological Investigation|April 1, 1993
Clinical thyroidology 1992: "what do we really need'?G Riccabona, L J DeGroot, F Delange, et al.
Pageof 9